Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Cobolimab

Research Leaders

6 sponsors active, led by Copenhagen University Hospital, Rigshospitalet

Related Conditions

Often studied with 16 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 15/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 1/2 (1)
Phase 4 (1)

Trial Status

Unknown1
Active Not Recruiting1
Completed1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT07358975Phase 4Not Yet RecruitingPrimary

Prediction of Complications in Hepatic Tumors

NCT06521567Phase 1/2Active Not Recruiting

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

NCT02202317Not ApplicableCompleted

Follow-up Yttrium-90 Internal Pair Production PET/CT vs Brehmsstrahlung Imaging in Patients With Primary/Metastatic Liver Tumors

NCT02503384Unknown

Clinical and Basic Study for Pediatric Liver Transplantation

Showing all 4 trials

Research Network

Common Treatments

  • Cobolimab1
  • 99mtc Tcgsa Spectct1
  • Petct Scan1
  • Dostarlimab1

Active Sponsors

  • Copenhagen University Hospital, Rigshospitalet1
  • GlaxoSmithKline Research & Development Limited1
  • Danish Cancer Society1
  • GSK1
  • RenJi Hospital1

Top Investigators

Related Conditions

  • Metabolic Disorders1
  • Hodgkin Lymphoma1
  • Fibrolamellar Carcinoma1
  • Liver Cancer1
  • Glioblastoma Multiforme Gbm1

Activity Timeline